Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — clinical trials in United Kingdom
30 open options
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Placebo (Study Part 1a) · ACI-24.060 at Dose A in Study Part 1a · ACI-24.060 at Dose B in Study Part 1a — 26 sites
- TRIALPHASE3RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
KarXT · Placebo — 129 sites
- TRIALNARECRUITING
Lived Experience Narratives in Dementia
Online LEND Intervention — 2 sites
- TRIALNARECRUITING
Microbiota Mediated Flavonoid Metabolites for Cognitive Health
Polyphenol Supplement · Placebo Supplement — 1 site
- TRIALPHASE3RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Xanomeline/Trospium Chloride Capsule · Xanomeline Enteric Capsule · Placebo — 145 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
KarXT · KarX-EC · KarXT + KarX-EC Arm Matching Placebo — 22 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug (SC) · Matching Placebo (Remternetug) — 37 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug · Matching Placebo (Remternetug) — 37 sites
- TRIALPHASE2ENROLLING_BY_INVITATION
TSPO Modulation in AD
XBD173 — 1 site
- TRIALPHASE1RECRUITING
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
RO7812653 · Placebo — 12 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
ALN-5288 · Placebo — 13 sites
- TRIALPHASE3RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
KarXT · Placebo — 154 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
DNL628 · Placebo — 4 sites
- TRIALPHASE1RECRUITING
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
LY3954068 · Placebo · Flortaucipir F18 — 10 sites
- TRIALPHASE3RECRUITING
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Acoramidis · Placebo oral tablet — 104 sites
- TRIALNANOT_YET_RECRUITING
Telerehabilitation of Balance Clinical and Economic Decision Support System
Full/High Tech Telerehabilitation decision support system · Basic/Low Tech Telerehabilitation decision support system · OTAGO Home exercise program — 5 sites
- TRIALPHASE1RECRUITING
A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK
NIO752 · Placebo — 2 sites
- TRIALPHASE2RECRUITING
Open-label Extension Study in Participants With Early Alzheimer's Disease
GSK4527226 — 33 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease
DNL921 · Placebo — 1 site
- TRIALNARECRUITING
Five Lives MED to Improve Cognitive Function in Mild Cognitive Impairment
Five Lives MED — 7 sites
- TRIALPHASE2 / PHASE3RECRUITING
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
EXV-802 · Placebo · EXV-801 — 49 sites
- TRIALNARECRUITING
Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)
BrainXpert · Placebo — 28 sites
- TRIALPHASE2RECRUITING
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
MK-2214 · Placebo — 80 sites
- TRIALPHASE3RECRUITING
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Trontinemab · Placebo — 143 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
KarXT · KarX-EC · Placebo — 126 sites
- TRIALPHASE2RECRUITING
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
VHB937 · VHB937 · Placebo — 74 sites
- TRIALPHASE3RECRUITING
An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease
Placebo · Atomoxetine · Metformin 1000 mg Oral Tablet — 2 sites
- TRIALPHASE3RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
KarXT — 429 sites
- TRIALPHASE3RECRUITING
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Trontinemab · Placebo — 150 sites
- TRIALNARECRUITING
The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological Conditions
Probiotic Supplementation with L. reuteri — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.